The FDA has approved Pfizer’s HER2-targeted drug Tukysa in combination with trastuzumab and pertuzumab as maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. The approval moves Tukysa, an oral tyrosine kinase inhibitor previously used in the second line since its 2020 debut, into the frontline setting as a chemotherapy-free maintenance option for patients whose disease has not progressed after initial treatment.
The decision rests on the Phase 3 HER2CLIMB-05 trial, which enrolled 654 patients who had completed four to eight cycles of induction therapy with trastuzumab, pertuzumab and a taxane without evidence of disease progression. Patients receiving Tukysa with the two antibodies had median progression-free survival of 24.9 months versus 16.3 months with placebo, an 8.6-month gain, and the risk of disease progression or death fell 35.9 percent (hazard ratio 0.64, p less than 0.0001). The PFS benefit held regardless of brain metastases or hormone receptor status. The safety profile was generally consistent with Tukysa’s known profile, though severe hepatotoxicity occurred in 3.9 percent of patients, including one fatal case of drug-induced liver injury.
Tucatinib’s ability to cross the blood-brain barrier is a meaningful feature in HER2-positive breast cancer, where brain metastases are common. The label expansion gives Pfizer a chemo-sparing option to offer earlier in the treatment sequence, at a time when the company’s oncology portfolio is leaning on the Seagen acquisition’s assets for growth. It also sharpens competition in frontline HER2-positive disease, where Roche’s Perjeta-based regimens and AstraZeneca and Daiichi Sankyo’s Enhertu antibody-drug conjugate define the standard of care.